Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal

 
• By Mandy Jackson

Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.

three capitals of granite columns displayed in a shop canteria - Image
Array's assets align with Pfizer's three oncology strategy pillars. • Source: Shutterstock

More from Deals

More from Business